TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29086911
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg phenylephrine
Study: 29086911
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg ephedrine
Study: 21818820
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemoradiotherapy
Study: 8957977
Drug: Suxamethonium-Mivacurium combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium-Mivacurium combination
Study: 8957977
Drug: Suxamethonium-Atracurium combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium-Atracurium combination
Study: 6832465
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream 0.25% and Dithranol stylus 0.2%
Study: 30638644
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil 0.7 μg/kg
Study: 28413993
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus oral weight based ribavirin for 24 weeks
Study: 28413993
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus oral weight based ribavirin and a 180 mcg Peg‐INF alpha 2a subcutaneous injection weekly for 12 weeks
Study: 25994549
Drug: FLU-v (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU-v (500 μg) and the adjuvant
Study: 24491069
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment sequences
Study: 19344076
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg daily for 12 weeks)
Study: 17942579
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (250 mmol [5.75 g] per day)
Study: 17942579
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake (70 mmol [1.61 g] per day)
Study: 8623970
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL bupivacaine 0.125% with 50 micrograms fentanyl followed by an infusion of 0.125% bupivacaine and 0.0002% fentanyl at 10 mL/h
Study: 8623970
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL bupivacaine 0.125% followed by an infusion of 0.125% bupivacaine at 10 mL/h
Study: 1611229
Drug: verlukast 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: verlukast 8 mg
Study: 1611229
Drug: verlukast 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: verlukast 2 mg
Study: 6689975
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5000 units two hours before operation and then 12-hourly for seven days)
Study: 6689975
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (same regimen as heparin)
Study: 30317965
Drug: Immediate nonfunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate nonfunctional loading of implants (20 implants)
Study: 30317965
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading protocol (19 implants)
Study: 28076671
Drug: MOMCare (Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOMCare (Brief Interpersonal Psychotherapy and/or antidepressants)
Study: 19657182
Drug: Enhanced tinnitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced tinnitus retraining therapy (TRT) including Jacobson's progressive muscle relaxation, physiotherapy, education via lectures, training of selective attention, and changes in appraisal, mental attitude, and behavior towards tinnitus.
Study: 10788964
Drug: Mivacurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.2 mg.kg‐1)
Study: 10788964
Drug: Succinylcholine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1.5 mg.kg‐1)
Study: 8794502
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (FD) dosage reduction
Study: 8794502
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FD dosage reduction)
Study: 1524625
Drug: Bronchoretard (theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoretard (theophylline sustained-release preparation)
Study: 1524625
Drug: Diffumal (theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diffumal (theophylline formulation of large consumption)
Study: 2867023
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg nocte
Study: 2867023
Drug: Pirenzepine 150
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 150 mg nocte
Study: 24479642
Drug: Supervised multi-purpose
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised multi-purpose exercise (MG)
Study: 18634442
Drug: Eviprostat tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eviprostat tablet (6 tabs/day)
Study: 18634442
Drug: EVI-F tablet
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVI-F tablet (3 tabs/day)
Study: 22229256
Drug: Subcutaneous gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6 mg)
Study: 20452196
Drug: SFC250 (salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC250 (salmeterol/fluticasone propionate combination 50/250 microg bd)
Study: 20452196
Drug: SFC500 (salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC500 (salmeterol/fluticasone propionate combination 50/500 microg bd)
Study: 17592691
Drug: Supported discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported discharge (home treatment)
Study: 12003257
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched spread (8.3% sterol content, 25 g/day)
Study: 22799613
Drug: Triple-combination treatment
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination treatment (OM 40 mg/AML 10 mg/HCTZ 25 mg)
Study: 22799613
Drug: Dual-combination treatments
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-combination treatments (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, or AML 10 mg/HCTZ 25 mg)
Study: 17278987
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril-based therapy, with possible addition of indapamide)
Study: 12681371
Drug: 0.23 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.23 mg/kg ketamine hydrochloride followed by 0.5 mg/kg ketamine over 45 min
Study: 1320287
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (4 mg q.i.d.)
Study: 6095322
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ACTH 4‐9 analog, ORG 2766
Study: 24299513
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy dressing (BioFOAM)
Study: 24299513
Drug: Hydrogel (Purilon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel (Purilon gel)
Study: 22540269
Drug: Radiopaque ENG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopaque ENG implant
Study: 22540269
Drug: Non-radiopaque ENG
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-radiopaque ENG implant
Study: 12066212
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine (5'‐DFUR)
Study: 12066212
Drug: Oral 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5‐fluorouracil (5‐FU)
Study: 9891531
Drug: 5‐FU injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU injections only (group B)
Study: 2962837
Drug: Procaterol 0.1
Normalized name: procaterol 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol 0.1 mg
Study: 12092746
Drug: Encapsulated enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated enteric-coated beads (400 mg)
Study: 12092746
Drug: Buffered tablet
Normalized name: CVS Aspirin 325mg Buffered Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered tablet (400 mg)
Study: 8697497
Drug: Mid-laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-laser treatment
Study: 31432220
Drug: FREEWAY™ drug‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: FREEWAY™ drug‐eluting balloon
Study: 26038960
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg formulation
Study: 26038960
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 100 mg formulation (reference product)
Study: 9730427
Drug: Intravenous Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tacrolimus
Study: 9730427
Drug: Oral Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tacrolimus
Study: 3292249
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (loading dose 20 mg/kg, maintenance dose 10 mg/kg per day)
Study: 29718460
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 2.4-0.4 mg/g nicotine
Study: 28538644
Drug: CD28 immunomodulator
Normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD28 immunomodulator (AB103) at 0.5 mg/kg, n = 15
Study: 21809698
Drug: phenibut tablets
Normalized name: phenibut
DrugBank: Phenibut (DB13455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenibut tablets
Study: 16409440
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg once daily (qd)
Study: 15700749
Drug: Hydroalcoholic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic extract of C. curvisepala Lind. (3 times daily for more than 4 months)
Study: 15700749
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily for more than 4 months)
Study: 1649718
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin treatment (36 units/kg intravenously three times a week for 6 months, then 18 units/kg three times a week for 6 months)
Study: 1649718
Drug: Desferrioxamine chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine chelation therapy (30 mg/kg intravenously three times a week for 6 months)
Study: 24149990
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream phonophoresis (2.5 % lidocaine, 2.5 % prilocaine)
Study: 18674741
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg orally thrice a day for 3 months)
Study: 10383539
Drug: Aqueous pump
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous pump spray 400 microg
Study: 9345419
Drug: 9 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 MIU intramuscular recombinant interferon alpha‐2a (rIFNA) (Roferon‐A, Roche) (n = 12)
Study: 9345419
Drug: rIFNA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFNA treatment
Study: 24717258
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + memantine (5 mg/d)
Study: 20598142
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of three medium hardboiled eggs
Study: 20598142
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of egg substitute for 6 weeks
Study: 12454298
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone and continuous nebulised salbutamol (US regimen)
Study: 12454298
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose prednisolone and bolus nebulised salbutamol (UK regimen)
Study: 10511066
Drug: Ascending dosing
Normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dosing pattern of methylphenidate
Study: 10511066
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing pattern of methylphenidate
Study: 10511066
Drug: Flat dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat dosing pattern of methylphenidate
Study: 8476617
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.25% bupivacaine with epinephrine (0.5 mg per 100 ml of solution)
Study: 8476617
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine with epinephrine (0.5 mg per 100 ml of solution)
Study: 8476617
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (40 ml of 0.25% bupivacaine and 20 ml of 0.5% bupivacaine)
Study: 3540875
Drug: Aspirin-caffeine-codeine-butalbital combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-caffeine-codeine-butalbital combination
Study: 8867523
Drug: Acetaminophen-codeine combination
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-codeine combination
Study: 30337315
Drug: Aussie-FIT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aussie-FIT intervention (12 weekly 90 min workshops)
Study: 26081224
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA capsules
Study: 26081224
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Dietary fish and n-3 PUFA capsules)
Study: 24194642
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injection (LAI) plus COMPASS (COMprehensive Psycho‐educational Approach and Scheme Set)
Study: 24194642
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injection (LAI) alone (control group)
Study: 21448219
Drug: Probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic milk drink (Yacult) consumed daily for 28 days
Study: 12627043
Drug: Transdermal estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol, 0.1 mg/day for 3 days
Study: 9987969
Drug: psychotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: psychotherapy with biofeedback + hypotensive drugs
Study: 9987969
Drug: hypotensive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypotensive drugs only
Study: 3042011
Drug: recombinant alpha‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant alpha‐interferon (rIFN‐alpha 2a2) in combination with etretinate
Study: 3042011
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (rIFN-alpha 2a2 + etretinate)
Study: 29141055
Drug: 1,064 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,064 nm laser treatment (5 monthly treatments)
Study: 29141055
Drug: 532 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532 nm laser treatment (4 monthly treatments)
Study: 18248658
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amitriptyline daily
Study: 25211369
Drug: ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with dabigatran (150 mg bid)
Study: 25211369
Drug: ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with rivaroxaban (20 mg od)
Study: 25211369
Drug: ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with phenprocoumon (INR 2.0‐3.0)
Study: 17627484
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg nightly for 4 weeks)
Study: 17627484
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically appearing tablet nightly for 4 weeks)
Study: 16235184
Drug: Thrice-weekly trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly trimethoprim-sulfamethoxazole (TS) for 12 weeks
Study: 11149033
Drug: Dopamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine + Mannitol (0.25 g/kg every 12 hours for 2 postoperative days)
Study: 11149033
Drug: Dopamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine + Furosemide (1 mg/kg every 12 hours for 2 postoperative days)
Study: 9489083
Drug: Nisoldipine coat
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat core (CC) 10 mg o.d.
Study: 9489083
Drug: Nisoldipine coat
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat core (CC)
Study: 7691765
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate in non-thrombolytic group
Study: 7691765
Drug: Ongoing fibrinolytic
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing fibrinolytic therapy
Study: 27807527
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical therapy group (PTG, n=23)
Study: 16061589
Drug: Additional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional analgesia with morphine
Study: 12370838
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS monotherapy (20 mg/d)
Study: 12370838
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (2.5 g/d)
Study: 12370838
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either glipizide GITS or metformin)
Study: 7672959
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation therapy (n = 8)
Study: 2149882
Drug: Remoxipride (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (high doses: 300-600 mg daily)
Study: 7023649
Drug: Weekly methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly methotrexate
Study: 7023649
Drug: Biweekly methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Biweekly methotrexate with leucovorin rescue (ML)
Study: 7023649
Drug: Biweekly ML
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly ML combined with cyclophosphamide and cytosine arabinoside (MLCC)
Study: 23484176
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide bleaching gel
Study: 16033337
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice (glucose 28 g in 250 ml) administered at 06:00‐06:30 am
Study: 2100642
Drug: Pliva 60
Normalized name: theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pliva 60 diltiazem preparation
Study: 2100642
Drug: Pliva 90
Normalized name: theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pliva 90 diltiazem preparation
Study: 2100642
Drug: Aldizem 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldizem 90 diltiazem preparation
Study: 6800954
Drug: Group Y
Normalized name: Neisseria meningitidis group Y Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Y vaccine
Study: 6800954
Drug: Group W135
Normalized name: Neisseria meningitidis serogroup W135 conjugated Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group W135 vaccine
Study: 6800954
Drug: Group Y-W135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Y-W135 combined vaccine
Study: 6800954
Drug: Monovalent vaccine
Normalized name: rotavirus, live, monovalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccine (50 micrograms)
Study: 6800954
Drug: Divalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalent vaccine (100 micrograms)
Study: 30157894
Drug: SWIS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWIS treatment (pre‐post‐follow‐up)
Study: 22205203
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 35 mg/m(2) in < 65 years group
Study: 22205203
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 20 mg/m(2) in ≥ 65 years group